Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment-- Drug development company Syntara reached 50% recruitment in its Phase 2 trial evaluating its lead candidate, SNT-5505, in combination with ruxolitinib, in the treatment of bone marrow cancer...